|
Study participant must be 40 to 75 years of age |
|
|
|
|
Study participant has Parkinson's Disease (PD), with a diagnosis made by a neurologist in the last 2 years (including diagnosis made at study screening) |
|
|
|
|
Study participant has the following symptoms: bradykinesia plus at least one of the following: muscular rigidity, or resting tremor |
|
|
|
|
A special imaging test called DaT-SPECT (Dopamine Transporter Imaging with Single Photon Emission Computed Tomography) done for the study or an already existing DaT-SPECT within the last 3 months confirms the diagnosis of PD |
|
|
|
|
Study participant meets the requirement of being in stage 2.5 of a special PD grading scale called “modified Hoehn and Yahr scale” |
|
|
|
|
Study participant has never taken medications for the treatment of motor symptoms of PD and is not expected to require symptomatic treatment in the next 6 months |
|
|
|
|
Study participant has never taken part in any research studies directed at a neurological disease with drugs that can change symptoms or progression of the disease |
|
|
|
|
Study participant can comply with all aspects of the study protocol, including following the study visit schedule and collection of biologic samples (for instance but not limited to blood and urine samples) |
|
|
|
|
A male participant must agree to use contraception during the Treatment Period and for at least 90 days after the last dose of study medication and refrain from donating sperm during this period |
|
|
|
|
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and she either cannot bear children, or agrees to use appropriate contraception during the treatment period and at least 1 month after the last dose of study medication. The study participant must have a negative serum pregnancy test at Screening (Visit 1), which is to confirmed negative by urine testing prior to the first dose of study medication at Baseline (Visit 3). If oral contraception is used, an additional barrier method will be required during the study |
|
|
|
|
Study participant has a known hypersensitivity to any components of the study medication or similar drugs
|
|
|
|
|
Study participant has a brain magnetic resonance imaging (MRI) scan performed during Screening or in the six months before that shows a relevant abnormality
|
|
|
|
|
Study participant cannot have a brain MRI or DaT-SPECT imaging scan performed for medical or other reasons
|
|
|
|
|
Study participant shows mild cognitive impairment or other significant cognitive impairment or clinical dementia at Screening according to a special scale called Montreal Cognitive Assessment (MoCA) with a score of less than 23
|
|
|
|
|
Study participant has abnormalities in the lumbar spine (spine in the lower back) that would interfere with a lumbar puncture (a procedure to collect fluid that surrounds the spinal cord)
|
|
|
|
|
Study participant has abnormalities in the electrocardiogram (ECG) results at Screening
|
|
|
|
|
Study participant has used medications for the treatment of motor symptoms of PD in the past (with the exception of short testing for confirmation of diagnosis) or has used drugs that can change symptoms or progression of PD
|
|
|
|